Atmika Paul

EDUCATION

College / University

Indian Institute of Technology, Madras

Highest Degree

MS (by research) in biological sciences

Major Subjects

Cancer Biology, Advanced Cellular and Molecular Biology, Human genetics, Developmental Biology, Vascular Biology.

Paul

Country

India

Lab Experience

Laboratory animal handling (RCULA certified); CRISPR-Cas9 mediated gene editing; confocal microscopy; live cell imaging; IHC, immunoblotting; qRT-PCR, flow cytometry and sorting; advanced cell culture techniques and functional assays; lentiviral particle generation and transduction; protein-protein interaction techniques; molecular cloning; Baculoviral expression system.

Projects / Research

  • 2015 – 2018 (IIT Madras, India): Functional characterization of RASSF7 as a critical regulator of cytoskeletal reorganization in metastatic breast cancer.
  • 2016 – 2018 (IIT Madras, India): 14-3-3σ upregulation in OSCC correlates with attenuated apoptosis and aberrant cell cycle regulation.
  • 2014 – 2015 (NIT Durgapur, India): Role of Monoamine oxidase A in ageing.

Scholarships / Awards

2019 – 2020: Stipend by the International Max Planck Research School
01/2019 – 07/2019: NUS, Singapore research fellowship
2015 – 2018: GATE scholarship in Biological Sciences, MHRD , India
2018: Awarded institute travel grant for Keystone symposia by IIT Madras, India
2015: Awarded GATEFORUM Study Scholarship (Top 100 rank holders in GATE Biotechnology)
2015: Awarded DBT Biotechnology Eligibility Test: Category I scholarship (Ranked Top 275 in India)
2014: Awarded Indian Academy of Sciences Summer Research Fellowship
2011: Awarded “Certificate of Merit” from CBSE for “Excellent academic performance and for being Top 0.1% candidates in Biology across India”

SCIENTIFIC INTERESTS AND GOALS

Having worked extensively on aberrant molecular signalling in cancer as part of my master’s thesis, my broad research interest lies in understanding the molecular basis of cancer through elucidation of key oncogenic signalling pathways and identification of molecular cancer drivers and rare oncogenic variants that enable cancer cells to maintain pro-tumorigenic hallmarks with an attempt to explore the therapeutic potential of these findings.